# Vtesse

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vtesse

- Industry: Pharmaceuticals
- Headquarters: Gaithersburg, US
- Website: www.vtessepharma.com
- Total disclosed funding: $39M
- Latest round: Series A (Mar 14, 2016)
- Investors on record: 5

## About

Vtesse, Inc. is a pharmaceutical company focused on developing and commercializing innovative treatments for rare diseases, particularly in the field of metabolic disorders, aiming to enhance patient care and outcomes.Vtesse, Inc. specializes in addressing rare metabolic diseases with targeted therapies. The company was acquired on April 3, 2017, by Sucampo Pharmaceuticals, Inc. for USD 200 mn from several venture-backed investors. Vtesse's headquarters is located in Gaithersburg, US. The acquisition marked a significant pivot in Vtesse's strategy to align with a larger entity specializing in pharmaceutical development and market reach.Vtesse, Inc. develops and commercializes pharmaceutical products aimed at treating rare metabolic disorders. The company’s primary focus includes innovative therapies that improve patient outcomes for individuals suffering from these conditions, ensuring a dedicated approach to enhancing quality of life for affected patients.Vtesse, Inc. generates revenue through strategic partnerships and direct sales to healthcare providers and institutions. The company’s revenue model is structured around agreements that facilitate the distribution of its proprietary treatments for rare diseases within specialized markets, primarily within the US healthcare sector.Vtesse, Inc. plans to expand its portfolio of rare disease treatments through the development of new products, leveraging recent funding from the acquisition by Sucampo Pharmaceuticals, Inc. The company aims to enhance its market presence in the US and is exploring opportunities in Europe and Asia by 2020. The funding will support research and development initiatives to bring innovative therapies to market, aligning with its growth strategy.

## Funding rounds

- Series A, Mar 14, 2016, $24M — New Enterprise Associates, Alexandria Venture Investments, Bay City Capital, Lundbeckfond Ventures, Pfizer Venture Investments
- Series A, Jan 7, 2015, $10M — New Enterprise Associates, Alexandria Venture Investments, Bay City Capital, Lundbeckfond Ventures, Pfizer Venture Investments
- Series A, Dec 4, 2014, $5.1M — New Enterprise Associates, Alexandria Venture Investments, Bay City Capital, Lundbeckfond Ventures, Pfizer Venture Investments

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series A
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A